2016 ACVIM Forum Research Abstract Program

While in vitro results cannot be directly correlated to in vivo efficacy, the results thus far indicate both drugs effectively suppress eicosanoid production after LPS stimulation, with an effect of both time and drug concentration. Based on the results of this study, a therapeutic dose of 2.5 µg/mL KT would effectively suppress eicosanoid production in cases of endotoxemia. Further research is needed to correlate in vitro results with in vivo efficacy. Hyperthermia in foals treated with erythromycin (ERY), clarithromycin, or azithromycin is associated with reduction of sweating by an unknown mechanism. The aims of this study were to evaluate effects on sweating of (1) chloramphenicol (CHL) which, like macrolides, binds to the 50S subunit of the bacterial ribosome and (2) gamithromycin (GAM), a macrolide sub-class 7a azalide which is not yet licensed for treatment of foals. Over 3 experimental periods, 12 foals (1 to 3 months old) were treated with ERY (25 mg/kg PO, 3 times daily for 5 days), GAM (8 mg/kg IM once) and CHL (50 mg/kg PO, 3 times daily for 5 days) according to a masked, duplicated, fully counterbalanced design. Quantitative intradermal terbutaline sweat tests were performed on 3 successive days before treatment (baseline) and on days 1, 2, 5, 9, 24, and 39 after treatment began. Data were analyzed by 1-, 2-, and 3-factor repeated measures ANOVA with post hoc pairwise analyses of significant tests. There was significant (P < 0. 05) suppression of sweating by ERY but not CHL or GAM. Compared with sweating at baseline, values when foals were given ERY were significantly lower on all test days except day 39. Sweating responses in foals given ERY were significantly lower than when given GAM or CHL on days 2, 5 and 9 at every terbutaline concentration except 100 lg/mL. In contrast, there was no difference between CHL and GAM. Results show that (1) ability to bind the bacterial 50S ribosome does not by itself confer potential to induce anhidrosis and (2) unlike the macrolides ERY and clarithromycin and the 9a-azalide azithromycin, the 7a-azalide GAM did not suppress sweating responses. have led to an increased awareness of this pathogen as a cause of colitis in adult horses. The objective of this study was to determine whether ECoV enterocolitis has a distinct clinical and/or clinicopathologic signature that can distinguish it from enteric salmonellosis or unknown causes of fever and neutropenia.